Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension

Ana García-Álvarez, Daniel Pereda, Inés García-Lunar, David Sanz-Rosa, Rodrigo Fernández-Jiménez, Jaime García-Prieto, Mario Nuño-Ayala, Federico Sierra, Evelyn Santiago, Elena Sandoval, Paula Campelos, Jaume Agüero, Gonzalo Pizarro, Víctor I. Peinado, Leticia Fernández-Friera, José M. García-Ruiz, Joan A. Barberá, Manuel Castellá, Manel Sabaté, Valentín FusterBorja Ibañez

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

Beta-3 adrenergic receptor (β3AR) agonists have been shown to produce vasodilation and prevention of ventricular remodeling in different conditions. Given that these biological functions are critical in pulmonary hypertension (PH), we aimed to demonstrate a beneficial effect of β3AR agonists in PH. An experimental study in pigs (n = 34) with chronic PH created by pulmonary vein banding was designed to evaluate the acute hemodynamic effect and the long-term effect of β3AR agonists on hemodynamics, vascular remodeling and RV performance in chronic PH. Ex vivo human experiments were performed to explore the expression of β3AR mRNA and the vasodilator response of β3AR agonists in pulmonary arteries. Single intravenous administration of the β3AR agonist BRL37344 produced a significant acute reduction in PVR, and two-weeks treatment with two different β3AR selective agonists, intravenous BRL37344 or oral mirabegron, resulted in a significant reduction in PVR (median of −2.0 Wood units/m2 for BRL37344 vs. +1.5 for vehicle, p = 0.04; and −1.8 Wood units/m2 for mirabegron vs. +1.6 for vehicle, p = 0.002) associated with a significant improvement in magnetic resonance-measured RV performance. Histological markers of pulmonary vascular proliferation (p27 and Ki67) were significantly attenuated in β3AR agonists-treated pigs. β3AR was expressed in human pulmonary arteries and β3AR agonists produced vasodilatation. β3AR agonists produced a significant reduction in PVR and improved RV performance in experimental PH, emerging as a potential novel approach for treating patients with chronic PH.

Original languageEnglish
Article number49
JournalBasic Research in Cardiology
Volume111
Issue number4
DOIs
StatePublished - 1 Jul 2016

Keywords

  • Beta-3 adrenergic receptor
  • Pulmonary hypertension
  • Pulmonary vascular resistance
  • Therapy

Fingerprint

Dive into the research topics of 'Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension'. Together they form a unique fingerprint.

Cite this